The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target

References

• Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009;6(2):76-85
   PubMedGoogle Scholar
• Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8(1):12-23
   PubMed Web of Science ®Google Scholar
• Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA Guideline. J Urol 2013;190:429-38
   PubMed Web of Science ®Google Scholar
• Saad F, Hotte SJ, Catton C, et al. CUA-CUOG guidelines for the management of castration resistant prostate cancer (CRPC): 2013. Can Urol Assoc J 2013;7:231-7
   PubMed Web of Science ®Google Scholar
• Machiels JP, Mazzeo F, Clausse M, et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008;26(32):5261-8
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
   PubMed Web of Science ®Google Scholar
• Madan RA, Pal SK, Sartor O, Dahut WL. Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res 2011;17:3892-902
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147-54
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10):983-92
   PubMed Web of Science ®Google Scholar
• Scher IH, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97
   PubMed Web of Science ®Google Scholar
• Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castrate-resistant prostate cancer. Eur Urol 2014;65(6):1198-204
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
   PubMed Web of Science ®Google Scholar
• Nilsson S, Franzén L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer 2013;11(1):20-6
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J. Med 2013;368:138-48
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Eisenberger MA. Phase III trials with docetaxel-based combinations for metastatic castration resistant prostate cancer: Time to learn from past experiences. J Clin Oncol 2013;31(14):1709-12
   PubMed Web of Science ®Google Scholar
• Solyanik GI. Multifactorial nature of tumor drug resistance. Exp Oncol 2010;32:181-5
   PubMedGoogle Scholar
• Paraiso KH, Smalley KS. Fibroblast-mediated drug resistance in cancer. Biochem Pharmacol 2013;85(8):1033-41
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8(10):755-68
   PubMed Web of Science ®Google Scholar
• Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 2013;85(9):1219-26
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009;15(16):5020-5
   PubMed Web of Science ®Google Scholar
• Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005;14(Suppl 1):35-48
   PubMed Web of Science ®Google Scholar
• Mahon KL, Henshall SM, Sutherland RL, Horvath LG. Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer 2011;18(4):R103-23
   Google Scholar
• Domingo-Domenech J, Oliva C, et al. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 2006;12(18):5578-86
   PubMed Web of Science ®Google Scholar
• Ischia J, Saad F, Gleave M. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer. Curr Opin Urol 2013;23(3):194-200
   PubMed Web of Science ®Google Scholar
• Liu W, Zhu F, Jiang Y, et al. siRNA targeting survivin inhibits the growth and enhances the chemosensitivity of hepatocellular carcinoma cells. Oncol Rep 2013;29(3):1183-8
   PubMed Web of Science ®Google Scholar
• Chi KN, Hotte SJ, Ellard S, et al. A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. J Clin Oncol 2012;30(5 Suppl):abstract 121
   Google Scholar
• So AI, Black PC, Chi KN, et al. A phase I trial of intravesical antisense oligonucleotide targeting heat shock protein 27 (OGX-427) for the treatment of non-muscle-invasive bladder cancer. J Clin Oncol 2012;30(5 Suppl):abstract 286
   Google Scholar
• Tolcher AW, Quinn DI, Ferrari A, et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol 2012;23(4):968-73
   PubMed Web of Science ®Google Scholar
• Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 2007;18(Suppl 5):v3-8
   PubMedGoogle Scholar
• Sánchez C, Mendoza P, Contreras HR, et al. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate 2009;69(13):1448-59
   PubMed Web of Science ®Google Scholar
• van Zuylen L, Sparreboom A, van der Gaast A, et al. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 2002;38(8):1090-9
   PubMed Web of Science ®Google Scholar
• Vrignaud P, Sémiond D, Lejeune P, et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res 2013;19(11):2973-83
   PubMed Web of Science ®Google Scholar
• Ploussard G, Terry S, Maillé P, et al. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res 2010;70(22):9253-64
   PubMed Web of Science ®Google Scholar
• Chi KN, Beardsley E, Eigl BJ, et al. A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Ann Oncol 2012;23(1):53-8
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110(3):556-63
   PubMed Web of Science ®Google Scholar
• Kurahashi T, Muramaki M, Yamanaka K, et al. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int 2005;96(6):895-9
   PubMed Web of Science ®Google Scholar
• Li H, Liu S, Zhu X, et al. Clusterin immunoexpression and its clinical significance in patients with non-small cell lung cancer. Lung 2010;188(5):423-31
   PubMed Web of Science ®Google Scholar
• Miyake H, Gleave M, Kamidono S, Hara I. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 2002;59(1):150-4
   PubMed Web of Science ®Google Scholar
• Redondo M, Villar E, Torres-Muñoz J, et al. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000;157(2):393-9
   PubMed Web of Science ®Google Scholar
• Steinberg J, Oyasu R, Lang S, et al. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997;3(10):1707-11
   PubMed Web of Science ®Google Scholar
• Henderson-Jackson EB, Nasir A, Chen DT, et al. Cytoplasmic Clusterin expression correlates with pancreatic neuroendocrine tumor size and pathological stage. Pancreas 2013;42(6):967-70
   PubMed Web of Science ®Google Scholar
• Tang M, Li J, Liu B, et al. Clusterin expression and human testicular seminoma. Med Hypotheses 2013;81(4):635-7
   PubMed Web of Science ®Google Scholar
• Liu B, Han MT, Zhang J, et al. Downregulation of clusterin expression in human testicular seminoma. Cell Physiol Biochem 2013;32(4):1117-23
   PubMed Web of Science ®Google Scholar
• July LV, Akbari M, Zellweger T, et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002;50(3):179-88
   PubMed Web of Science ®Google Scholar
• Sowery RD, Hadaschik BA, So AI, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008;102(3):389-97
   PubMed Web of Science ®Google Scholar
• Patterson SG, Wei S, Chen X, et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 2006;25(45):6113-22
   PubMed Web of Science ®Google Scholar
• Zellweger T, Chi K, Miyake H, et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002;8(10):3276-84
   PubMed Web of Science ®Google Scholar
• Rizzi F, Bettuzzi S. Clusterin (CLU) and prostate cancer. Adv Cancer Res 2009;105:1-19
   PubMed Web of Science ®Google Scholar
• Mydlarz W, Uemura M, Ahn S, et al. Clusterin is a gene-specific target of microRNA-21 in head and neck squamous cell carcinoma. Clin Cancer Res 2014;20(4):868-77
   PubMed Web of Science ®Google Scholar
• Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010;16:1088-93
   PubMed Web of Science ®Google Scholar
• Zoubeidi A, Gleave M. Small heat shock proteins in cancer therapy and prognosis. Int J Biochem Cell Biol 2012;44(10):1646-56
   PubMed Web of Science ®Google Scholar
• Michel D, Chatelain G, North S, Brun G. Stress-induced transcription of the clusterin/apoJ gene. Biochem J 1997;328(Pt 1):45-50
   PubMed Web of Science ®Google Scholar
• Vabulas RM, Raychaudhuri S, Hayer-Hartl M, Hartl FU. Protein folding in the cytoplasm and the heat shock response. Cold Spring Harb Perspect Biol 2010;2(12):a004390
   Google Scholar
• Yang CR, Leskov K, Hosley-Eberlein K, et al. Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci U S A 2000;97(11):5907-12
   PubMed Web of Science ®Google Scholar
• Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995;27(7):633-45
   PubMed Web of Science ®Google Scholar
• Yu JT, Tan L. The role of clusterin in Alzheimer’s disease: pathways, pathogenesis, and therapy. Mol Neurobiol 2012;45(2):314-26
   PubMed Web of Science ®Google Scholar
• Yerbury JJ, Poon S, Meehan S, et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J 2007;21(10):2312-22
   PubMed Web of Science ®Google Scholar
• Sensibar JA, Sutkowski DM, Raffo A, et al. Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res 1995;55(11):2431-7
   PubMed Web of Science ®Google Scholar
• Zhang H, Kim JK, Edwards CA, et al. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005;7(9):909-15
   PubMed Web of Science ®Google Scholar
• Shiota M, Zardan A, Takeuchi A, et al. Clusterin mediates TGF-β induced epithelial–mesenchymal transition and metastasis via Twist-1 in prostate cancer cells. Cancer Res 2012;72:5261-72
   PubMed Web of Science ®Google Scholar
• Gleave ME, Miyake H, Zellweger T, et al. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 2001;58(Suppl 1):29-49
   Google Scholar
• So A, Sinnemann S, Huntsman D, et al. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther 2005;4(12):1837-49
   PubMed Web of Science ®Google Scholar
• July LV, Beraldi E, So A, et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 2004;3(3):223-32
   PubMed Web of Science ®Google Scholar
• Muramaki M, So A, Hayashi N, et al. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene. clusterin. BJU Int 2009;103(3):384-90
   PubMed Web of Science ®Google Scholar
• Cao C, Shinohara ET, Li H, et al. Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. Int J Radiat Oncol Biol Phys 2005;63(4):1228-36
   PubMed Web of Science ®Google Scholar
• Zellweger T, Miyake H, Cooper S, et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 2001;298(3):934-40
   PubMed Web of Science ®Google Scholar
• Henry S, Stecker K, Brooks D, et al. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther 2000;292(2):468-79
   PubMed Web of Science ®Google Scholar
• Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005;97(17):1287-96
   PubMed Web of Science ®Google Scholar
• Chi KN, Goldenberg L, Kollmannsberger C, et al. A phase II neoadjuvant study of OGX-011, a 2’methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to prostatectomy [abstract 167]. Presented at American Society of Clinical Oncology Genitourinary Cancers Symposium. San Francisco, USA, 14–16 February, 2008
   Google Scholar
• Chi KN, Siu LL, Hirte H, et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008;14(3):833-9
   PubMed Web of Science ®Google Scholar
• Chi KN, Hotte SJ, Yu EY, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28(27):4247-54
   PubMed Web of Science ®Google Scholar
• Saad F, Hotte S, North S, et al. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG Trial P-06. Clin Cancer Res 2011;17:5765-73
   PubMed Web of Science ®Google Scholar
• Jankovic B, Beardsley E, Chi KN. Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) after previous docetaxel: a population based analysis. Presented at American Society of Clinical Oncology Genitourinary Cancers Symposium. San Francisco, USA, 14–16 February 2008. Abstract 196
   Google Scholar
• Berthold DR, Pond GR, de Wit R, Eisenberger M; Tannock IF, for the TAX 327 Investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19(10):1749-53
   PubMed Web of Science ®Google Scholar
• Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY). Available from: https://clinicaltrials.gov/ct2/show/NCT01188187
   Google Scholar
• Chi KN, de Bono JS, Higano CS. SYNERGY: A randomized phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol 2011;29(15 Suppl):abstract TPS180
   Google Scholar
• Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY). Available from: https://clinicaltrials.gov/ct2/show/NCT01578655
   Google Scholar
• Beer TM, Blumstein BA, Fizazi K, et al. Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2013;31(15 Suppl):abstract TPS5103
   Google Scholar
• A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01630733
   Google Scholar
• Miyake H, Hara I, Fujisawa M, Gleave ME. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. Expert Opin Investig Drugs 2006;15(5):507-17
   PubMed Web of Science ®Google Scholar
• Doustjalali SR, Yusof R, Yip CH, et al. Aberrant expression of acute-phase reactant proteins in sera and breast lesions of patients with malignant and benign breast tumors. Electrophoresis 2004;25:2392-401
   PubMed Web of Science ®Google Scholar
• Stejskal D, Fiala RR. Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer. Neoplasma 2006;53:343-6
   PubMed Web of Science ®Google Scholar
• Blumenstein B, Saad F, Hotte S, et al. Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. Cancer Med 2013;2(4):468-77
   Google Scholar
• Laskin JJ, Nicholas G, Lee C, et al. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol 2012;7(3):579-86
   PubMed Web of Science ®Google Scholar
• van Soest RJ, van Royen ME, de Morrée ES, et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013;49:3821-30
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Fizazi K, Sternberg C, et al. A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients with castrate-resistant prostate cancer (CRPC): The MAINSAIL Trial [abstract LBA24]. Presented at European Society of Molecular Oncology Congress, Berlin, Germany, 2012
   Google Scholar
• Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30(13):1534-40
   PubMed Web of Science ®Google Scholar
• Tannock I, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel and prednisone treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 2013;14(8):760-8
   PubMed Web of Science ®Google Scholar
• Fizazi K, Higano C, Nelson J, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2013;31(14):1740-7
   PubMed Web of Science ®Google Scholar
• Araujo JC, Trudel GC, Saad F, et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. J Clin Oncol 2013;31(6 Suppl):abstract LBA8
   Google Scholar
• Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011;29(16):2191-8
   PubMed Web of Science ®Google Scholar
• Docetaxel and Prednisone With or Without OGX-011 in Treating Patients With Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy. Available from: https://clinicaltrials.gov/ct2/show/NCT00258388
   Google Scholar
• Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC. Available from: https://clinicaltrials.gov/ct2/show/NCT00327340
   Google Scholar